IA
CRDL

Integrity Alliance’s Cardiol Therapeutics CRDL Stock Holding History

Integrity Alliance’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$630K Buy
465,025
+30,000
+7% +$30.8K 0.02% 392
2025
Q4 		$416K Buy
+435,025
New +$456K 0.02% 513

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Integrity Alliance's CRDL Position: Q1 2026 in Review

Integrity Alliance increased its Cardiol Therapeutics (CRDL) stake by 6.9% in Q1 2026, buying an estimated $30.8K and bringing the position to 465,025 shares worth $630K. The position accounts for 0.02% of the portfolio, ranked #392.

Integrity Alliance first reported a position in CRDL in Q4 2025 and has held it in 2 quarters since. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Integrity Alliance held 465,025 shares of Cardiol Therapeutics worth $630K as of Q1 2026.
  • Integrity Alliance bought 30,000 Cardiol Therapeutics shares in Q1 2026, an estimated $30.8K.
  • Cardiol Therapeutics made up 0.02% of Integrity Alliance's portfolio in Q1 2026, its #392 holding.
  • Integrity Alliance first reported a position in Cardiol Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Integrity Alliance's 13F filing for Q1 2026, filed 11 May 2026.